Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: Procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal

Journal of Nuclear Medicine

Volumn 47, Issue 4, 2006, Pages 648-654

  Hänscheid, Heribert ^a   Lassmann, Michael ^a   Luster, Markus ^a   Thomas, Stephen R ^b   Pacini, Furio ^c,d   Ceccarelli, Claudia ^c   Ladenson, Paul W ^e   Wahl, Richard L ^e   Schlumberger, Martin ^f   Ricard, Marcel ^f   Driedger, Al ^g   Kloos, Richard T ^h   Sherman, Steven I ⁱ   Haugen, Bryan R ^j   Carriere, Vincent ^k   Corone, Carine ^k   Reiners, Christoph ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f INSTITUT GUSTAVE ROUSSY   (France)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k CENTRE RENÉ HUGUENIN   (France)

more..

Author keywords

Blood dose; Differentiated thyroid cancer; Dosimetry; Radioiodine therapy; rhTSH

Indexed keywords

IODINE; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROID HORMONE; RADIOACTIVE IODINE; RECOMBINANT PROTEIN; THYROTROPIN; THYROXINE;

ARTICLE; BLOOD SAMPLING; CATHETER ABLATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSIMETRY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG UPTAKE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCINTIGRAPHY; THYROID CANCER; THYROIDECTOMY; ADULT; DRUG EFFECT; INTERNATIONAL COOPERATION; METABOLISM; PATHOLOGY; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION EXPOSURE; THYROID GLAND; THYROID TUMOR; WHOLE BODY COUNTING;

ADULT; HUMANS; INTERNATIONAL COOPERATION; IODINE RADIOISOTOPES; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RECOMBINANT PROTEINS; THYROID GLAND; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; WHOLE-BODY COUNTING;

EID: 33745071291     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Benua RS, Cicale NR, Sonenberg M, Rawson RW. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. 1962;87:171-182.
2. Maxon HR 3rd, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19:685-718.
3. Thomas SR, Samaratunga RC, Sperling M, Maxon HR 3rd. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol. 1993;20:157-162.
4. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451-456.
5. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84:3877-3885.
6. Robbins RJ, Larson SM, Sinha N, et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med. 2002;43:1482-1488.
7. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88:4110-4115.
8. 131I. J Nucl Med. 2003;44:898-903.
9. Pacini F, Molinaro E, Castagna MG, et al. Ablation of thyroid residues with 30 mCi 131-I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87:4063-4068.
10. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. December 29, 2005 [Epub ahead of print].
11. 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med. 2004;45:1549-1554.
12. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30:1371-1377.
13. National Electrical Manufacturers Association (NEMA). Performance Measurements of Scintillation Cameras. Standards Publication NU 1-2001. Washington DC: NEMA; 2001.
14. Akabani G, Poston JW Sr. Absorbed dose calculations to blood and blood vessels for internally deposited radionuclides. J Nucl Med. 1991;32:830-834.
15. Snyder WS, Ford MR, Warner GG, Watson SB. "S" Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. MIRD Pamphlet No. 11. New York, NY: Society of Nuclear Medicine; 1975.
16. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023-1027.
17. Barrett PH, Bell BM, Cobelli C, et al. SAAM II: simulation, analysis, and modeling software for tracer and pharmacokinetic studies. Metabolism. 1998;47:484-492.
18. 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes. J Nucl Med. 2004;45:608-611.
19. Monsieurs MA, Thierens HM, van de Wiele CV, et al. Estimation of risk based on biological dosimetry for patients treated with radioiodine. Nucl Med Commun. 1999;20:911-917.
20. M'Kacher R, Schlumberger M, Legal JD, et al. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131. J Nucl Med. 1998;39:825-829.
21. Lassmann M, Hanscheid H, Reiners C, Thomas SR. Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH. J Nucl Med. 2005;46:900-901.